DNMT3A and acute myeloid leukemia: Our results show that possibly DNMT3A‐NPM1 mutated AML is as sensible to combinations of PARP inhibitors plus anthracyclines, but not to the combination of PARP inhibitors and hypomethylating agents, at least in a pre‐clinical setting.